Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Recce Pharmaceuticals Ltd. ( (AU:RCE) ) is now available.
Recce Pharmaceuticals Ltd has announced an extension of the closing date for its pro-rata non-renounceable entitlement offer, allowing eligible shareholders more time to participate. The offer aims to raise up to $10.8 million and provides an opportunity for shareholders to apply for additional shares under the shortfall offer, potentially impacting the company’s financial position and market operations.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a company focused on developing a new class of synthetic anti-infectives to tackle antibiotic-resistant superbugs. Their product pipeline includes three patented anti-infectives: RECCE 327 for serious bacterial infections, RECCE 435 for oral bacterial infections, and RECCE 529 for viral infections. The company has received recognition from the World Health Organization and the FDA for its innovative approach to combating antimicrobial resistance.
YTD Price Performance: -40.62%
Average Trading Volume: 218,413
Technical Sentiment Signal: Buy
Current Market Cap: A$77.1M
See more insights into RCE stock on TipRanks’ Stock Analysis page.